Selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitors and epidemiological characteristics associated with prenatal diagnosis of congenital heart disease

Prenat Diagn. 2021 Jan;41(1):35-42. doi: 10.1002/pd.5846. Epub 2020 Nov 3.

Abstract

Objective: Identify early pregnancy associations of congenital heart disease (CHD) in a multiethnic cohort.

Methods: This retrospective observational cohort study compared the general obstetric population to women who gave birth at a referral centre in Australia between 2012 and 2017, after 20 weeks' of gestation, with a pregnancy affected by CHD. We defined mood disorder and anxiety as a history of self-reported or medically diagnosed anxiety, depression, postpartum depression or bipolar disorder.

Results: We compared epidemiological factors between 30 842 general obstetric patients and 470 obstetric patients with a foetus affected by CHD. Multivariate analysis showed independent associations between CHD and use of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in the first trimester (relative risk [RR] 4.14, 95% CI 2.58-6.65), history of anxiety or mood disorder with no SSRI/SNRI first trimester (RR 2.20, 95% CI 1.77-2.74), folate and/or pregnancy multivitamin use in the first trimester (RR 0.69, 95% CI 0.55-0.87) and increased risk with maternal age >40 years (RR 2.30, 95% CI 1.57-3.38).

Conclusions: Our data show maternal mood disorders with and without SSRI or SNRI use, maternal age >40 years and lack of multivitamin/folate use to be independently associated with CHD in pregnancy.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Female
  • Heart Defects, Congenital / chemically induced
  • Heart Defects, Congenital / diagnosis
  • Heart Defects, Congenital / epidemiology*
  • Humans
  • New South Wales / epidemiology
  • Pregnancy
  • Prenatal Diagnosis
  • Prenatal Exposure Delayed Effects*
  • Retrospective Studies
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Serotonin and Noradrenaline Reuptake Inhibitors / adverse effects*
  • Tertiary Care Centers / statistics & numerical data
  • Young Adult

Substances

  • Serotonin Uptake Inhibitors
  • Serotonin and Noradrenaline Reuptake Inhibitors